Outset Medical, Inc. $OM Shares Sold by Marshall Wace LLP

Marshall Wace LLP cut its position in shares of Outset Medical, Inc. (NASDAQ:OM) by 19.8% during the 2nd quarter, Holdings Channel reports. The firm owned 521,400 shares of the company’s stock after selling 128,864 shares during the period. Marshall Wace LLP’s holdings in Outset Medical were worth $10,016,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Woodline Partners LP acquired a new stake in shares of Outset Medical in the first quarter valued at $14,663,000. Geode Capital Management LLC raised its position in Outset Medical by 955.9% in the second quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock worth $7,984,000 after acquiring an additional 376,196 shares in the last quarter. Pura Vida Investments LLC raised its position in Outset Medical by 8,482.4% in the second quarter. Pura Vida Investments LLC now owns 429,120 shares of the company’s stock worth $8,243,000 after acquiring an additional 424,120 shares in the last quarter. Parkman Healthcare Partners LLC acquired a new stake in Outset Medical in the 1st quarter valued at about $2,556,000. Finally, Alyeska Investment Group L.P. bought a new position in shares of Outset Medical during the 1st quarter valued at about $18,836,000.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Royal Bank Of Canada dropped their target price on shares of Outset Medical from $22.00 to $17.00 and set a “sector perform” rating on the stock in a report on Tuesday, November 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research report on Monday. Stifel Nicolaus set a $14.00 price target on Outset Medical and gave the company a “buy” rating in a report on Tuesday, November 11th. BTIG Research reduced their price objective on Outset Medical from $39.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, November 11th. Finally, Wall Street Zen cut Outset Medical from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Outset Medical Stock Up 0.9%

OM stock opened at $4.40 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 7.09 and a quick ratio of 5.77. The firm has a market capitalization of $79.86 million, a P/E ratio of -0.34 and a beta of 2.03. Outset Medical, Inc. has a 52-week low of $4.00 and a 52-week high of $25.35. The company’s 50 day simple moving average is $9.75 and its 200-day simple moving average is $14.25.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.